24.04.2024 03:36:45 - dpa-AFX: GNW-Adhoc: Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals
plc (http://www.centessa.com/) (Nasdaq: CNTA), a clinical-stage pharmaceutical
company that aims to discover and develop medicines that are transformational
for patients, today announced the pricing of an underwritten public offering of
10,810,810 American Depositary Shares ("ADSs"), each representing one ordinary
share, at a price to the public of $9.25 per ADS. The aggregate gross proceeds
to Centessa from this offering are expected to be approximately $100 million,
before deducting underwriting discounts and commissions and offering expenses
payable by Centessa. All ADSs sold in the offering were offered by Centessa. The
offering is expected to close on or about April 26, 2024, subject to customary
closing conditions. Centessa has also granted the underwriters a 30-day option
to purchase up to an additional 1,621,621 ADSs at the public offering price,
less underwriting discounts and commissions.
Goldman Sachs, Leerink Partners, Evercore ISI, Guggenheim Securities and BMO
Capital Markets are acting as joint book-running managers for the offering.
The ADSs are being offered pursuant to a registration statement on Form S-3 that
was previously filed with, and subsequently declared effective on July 12, 2022
by, the Securities and Exchange Commission ("SEC"). A preliminary prospectus
supplement and accompanying prospectus relating to the offering have been
filed, and a final prospectus supplement and accompanying prospectus related to
the offering will be filed, with the SEC and are or will be available on the
SEC's website located at http://www.sec.gov. Copies of the final prospectus
supplement and the accompanying prospectus relating to the offering, when
available, may be obtained from: Goldman Sachs & Co. LLC, Attn: Prospectus
Department, 200 West Street, New York, New York 10282, telephone:
1-866-471-2526, email: prospectus-ny@ny.email.gs.com; Leerink Partners LLC,
Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by
telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com
(mailto:syndicate@leerink.com); Evercore Group L.L.C., Attention: Equity Capital
Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at
(888) 474-0200, or by email at ecm.prospectus@evercore.com; Guggenheim
Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue,
8(th) Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email
at GSEquityProspectusDelivery@guggenheimpartners.com
(mailto:GSEquityProspectusDelivery@guggenheimpartners.com); or BMO Capital
Markets Corp., Attention: Equity Syndicate Department, 151 W 42nd Street, 32nd
Floor, New York, New York 10036, by telephone at (800) 414-3627 or by email at:
bmoprospectus@bmo.com.
This press release shall not constitute an offer to sell or the solicitation of
an offer to buy these securities, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc (http://www.centessa.com/) is a clinical-stage
pharmaceutical company that aims to discover and develop transformational
medicines for patients. Our most advanced programs include a hemophilia program,
an orexin agonist program for the treatment of narcolepsy and other sleep-wake
disorders and an immuno-oncology program focused on our LockBody® technology
platform. We operate with the conviction that each of our programs has the
potential to change the current treatment paradigm and establish a new standard
of care.
Forward Looking Statements
This press release contains forward-looking statements. Any such statements in
this press release that are not statements of historical fact may be deemed to
be forward-looking statements, including those relating to Centessa's
expectations with respect to the completion and timing of the public
offering. Any forward-looking statements in this press release are based on our
current expectations, estimates and projections only as of the date of this
release and are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set forth in or
implied by such forward-looking statements. These risks and uncertainties
related to completion of the proposed public offering and the satisfaction of
customary closing conditions related to the public offering. Risks concerning
our programs and operations are described in additional detail in our Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q, and our other reports,
which are on file with the U.S. Securities and Exchange Commission (SEC). We
explicitly disclaim any obligation to update any forward-looking statements
except to the extent required by law.
Contact:
Kristen K. Sheppard, Esq.
SVP of Investor Relations
investors@centessa.com (mailto:investors@centessa.com)
Â